ESC Congress in Munich puts Alnylam's heart drugs under scrutiny after rival failure
The European Society of Cardiology meeting in Munich will focus on Alnylam Pharmaceuticals as new data show a competing drug, eplontersen, failed to lower cardiovascular death risk.
The European Society of Cardiology Congress kicking off Friday in Munich will draw attention to Alnylam Pharmaceuticals because its two ATTR-CM therapies now face an uncertain outlook. AstraZeneca and Ionis Pharmaceuticals presented data indicating their rival drug eplontersen did not significantly reduce cardiovascular mortality or recurrent events versus placebo. The unexpected result raises questions about the market prospects for Alnylam's heart-failure candidates, prompting investors and cardiologists to seek further insight at the conference.
Why it matters
The trial setback for a rival drug influences investor confidence and patient expectations for Alnylam's heart treatments.
In this story
